{"entity":{"id":"sinotau-pharmaceutical","kind":"company","name":"Sinotau Pharmaceutical","aka":["Sinotau Pharmaceutical Group"],"tldr":"Sinotau Pharmaceutical is a China-based radiopharmaceutical company running 2 late-stage cancer trials of Octreotide LAR in neuroendocrine tumours.","summary":"Sinotau Pharmaceutical, based in Beijing, China, is a radiopharmaceutical company. Sinotau specialises in the research and development, production, clinical application and academic promotion of radiopharmaceutical drugs, with therapeutic focus areas in oncology, neurology and cardiology. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials (2 in phase 3), testing Octreotide LAR in neuroendocrine tumours. The largest, NCT05459844 (A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs), plans to enrol 196 participants (actual). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.sinotau.com/"},{"label":"ClinicalTrials.gov: trials led by Sinotau Pharmaceutical","url":"https://clinicaltrials.gov/search?lead=Sinotau%20Pharmaceutical%20Group"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["neuroendocrine"],"sections":["radiopharma"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":["nct05459844","nct06398444"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Beijing","country":"CN","companyType":"radiopharma","website":"https://www.sinotau.com/","founded":2014,"stage":"private-large","investors":[],"funding":[]},"route":"/companies/sinotau-pharmaceutical/","neighbours":{"cancer":[{"id":"neuroendocrine","kind":"cancer","name":"Neuroendocrine tumours","route":"/cancers/neuroendocrine/"}],"section":[{"id":"radiopharma","kind":"section","name":"Radiopharmaceuticals & Theranostics","route":"/fronts/radiopharma/"}],"term":[{"id":"clinical-trial","kind":"term","name":"Clinical trial","route":"/terms/clinical-trial/"},{"id":"pivotal-trial","kind":"term","name":"Pivotal (registrational) trial","route":"/terms/pivotal-trial/"}],"trial":[{"id":"nct06398444","kind":"trial","name":"A Clinical Study of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine Neoplasms","route":"/trials/nct06398444/"},{"id":"nct05459844","kind":"trial","name":"A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs","route":"/trials/nct05459844/"}]}}